Enter your keywords
HOME
About Us
NEWSLETTER
To search AlzGene, use the "Keyword" search on the
AlzGene search page
.
NEWS
All News
Conference Coverage
Series
WEBINARS
All Webinars
Databases
AlzBiomarker
AlzPedia
AlzRisk
Antibodies
Genetics
AlzGene
HEX
Mutations
Protocols
Research Models
Therapeutics
PAPERS
All Papers
Papers of the Week
Milestone
Alzforum Recommends
PROFESSIONAL RESOURCES
Conference Calendar
Grants
Jobs
Member Directory
ABOUT AD
AD Overview
Early-Onset Familial
The HBO Alzheimer's Project
Supported Browsers
MY ALZFORUM
My AlzForum Home
View Library
View Notifications
Set Notifications
Edit Profile
AlzGene - Gene overview of all published AD-association studies for APOE
Gene:
APOE
(AD2; MGC1571)
View on ALSGene
View on MSGene
View on PDGene
View on SZGene
Protein:
apolipoprotein E
(Alzheimer disease 2)
Chromosome:
19
(View:
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
X
Y
MT
)
Status:
Updated 18 April 2011
1. Case-Control Studies (by ethnic group)
AD Cases
Normal Controls
Study
Population
Source
# Polys
# Subjects
(% women)
DX
Onset Age
(range)
Age
(range)
# Subjects
(% women)
Age
(range)
Result
Comment
Caucasian
Abraham, 2008
GWAS
CL
2
(detail)
1082
(71%)
C
75.8 + 6.8
(60-95)
-
1239
(-)
76.5 + 6.3
(-)
Positive
Ahmed, 1999
UK
CL
1
(detail)
96
(67%)
N
-
-
53
(34%)
-
Positive
Alvarez-Arcaya, 2001
Spain
CL
1
(detail)
251
(68%)
C
71.5 + 9.1
(40-95)
75.3 + 9.3
(50-98)
251
(70%)
79.9 + 7.9
(63-98)
Positive
Artiga, 1998
Overlaps with
Bullido, 1998 (Spain)
CL
2
(detail)
-
-
-
-
-
-
n.a.
Artiga, 1998
Overlaps with
Bullido, 1998 (USA)
CL
2
(detail)
-
-
-
-
-
-
n.a.
Bahia, 2008
Brazil
CL
2
(detail)
120
(68%)
C
71.1 + 9.5
(-)
75.2 + 9.2
(-)
120
(63%)
72.5 + 8.6
(-)
Positive
Beecham, 2009
GWAS
CL
0
492
(61%)
M
72.9 + 6.6
(-)
-
496
(63%)
74.3 + 6.5
(-)
Positive
Belbin, 2007
UK
CL
5
(detail)
395
(57%)
M
75.6 + 10.5
(-)
-
324
(49%)
75.3 + 9.4
(-)
Positive
Beyer, 2002a
Spain
CL
2
(detail)
183
(62%)
C
-
70.8
(48-85)
169
(60%)
68.7
(45-84)
Positive
Beyer, 2002b
Overlaps with
Beyer, 2002a
2
(detail)
-
-
-
-
-
-
n.a.
Beyer, 2005
Overlaps with
Beyer, 2002a
CL
1
(detail)
206
(62%)
C
-
72.6
(48-85)
181
(60%)
69.6
(45-84)
n.a.
Bizzarro, 2009
Italy
CL
3
(detail)
169
(69%)
C
-
63.3 + 7.3
(-)
99
(49%)
66.2 + 7.3
(-)
Positive
Bullido, 1998
Spain
CL
1
(detail)
110
(-)
C
68 + 5
(-)
-
132
(-)
72 + 7
(-)
Positive
Bullido, 1998
USA
CL
1
(detail)
160
(-)
C
75 + 8
(-)
-
175
(-)
78 + 9
(-)
Positive
Bullido, 2000
Overlaps with
Bullido, 1998 (Spain)
CL
4
(detail)
154
(60%)
C
70.4 + 6.3
(-)
-
217
(62%)
72 + 7.6
(-)
Positive
Carrasquillo, 2009
GWAS (Stage I)
CL
2
(detail)
844
(57%)
M
74 + 4.8
(-)
-
1255
(51%)
73.2 + 4.4
(-)
Positive
Carrasquillo, 2009
GWAS (Stage II)
CL
2
(detail)
1547
(65%)
M
81.1 + 7.8
(-)
-
1209
(58%)
83.3 + 5.6
(-)
Positive
Casadei, 1999
Italy
CL
1
(detail)
358
(63%)
C
67.3 + 9.3
(-)
-
367
(41%)
63.2 + 12.5
(-)
Positive
Chalmers, 2004
UK
CL
2
(detail)
86
(53%)
N
-
79.5 + 7.2
(60-93)
58
(41%)
78.8 + 8.2
(62-95)
Negative
Clarimon, 2003
Spain
1
(detail)
112
(73%)
C
-
76.7 + 5.4
(-)
89
(53%)
74.8 + 5.2
(-)
Positive
Coon, 2007
GWAS
0
-
-
-
-
-
-
Positive
Corder, 2006
Overlaps with
Parker, 2005
CL
2
(detail)
-
-
-
-
-
-
n.a.
Emahazion, 2001
Scotland
CL
1
(detail)
121
(-)
C
-
-
152
(-)
-
Negative
Giedraitis, 2009
GWAS
CL
0
86
(0%)
C
80.2
(72-85)
-
404
(0%)
81.8
(80-84)
Positive
Giedraitis, 2009
Sweden (ULSAM)
CL
2
(detail)
86
(0%)
C
80.2
(72-85)
-
404
(0%)
81.8
(80-84)
Negative
Grupe, 2007
UK1
CL
1
(detail)
380
(77%)
M
75.7 + 7.1
(-)
-
396
(75%)
76.6 + 6.2
(-)
Positive
Grupe, 2007
UK2
CL
1
(detail)
309
(73%)
M
76.3 + 7
(-)
-
349
(57%)
76.7 + 5.6
(-)
Positive
Grupe, 2007
UK3
CL
1
(detail)
503
(64%)
M
75.1 + 6.5
(-)
-
643
(59%)
76.1 + 6.4
(-)
Positive
Grupe, 2007
USA (WashU)
CL
1
(detail)
376
(63%)
M
76.3 + 7
(-)
-
349
(57%)
76.7 + 5.6
(-)
Positive
Grupe, 2007
USA (UCSD)
CL
1
(detail)
240
(45%)
M
72 + 6.2
(-)
-
330
(63%)
79.3 + 7.2
(-)
Positive
Halimi, 2000
France
CL
1
(detail)
281
(-)
C
-
76.9 + 8.3
(-)
84
(-)
77 + 7.4
(-)
Negative
Han, 2010
* Recently Added *
Overlaps with
Kim, 2011
CL
1
(detail)
172
(39%)
C
-
71
(-)
109
(46%)
71.7
(-)
Positive
Harold, 2009
GWAS
CL
0
3941
(63%)
M
72.7
(-)
-
7848
(53%)
55.6
(-)
Positive
Harold, 2009
Stage 1 (UK, Ireland)
CL
2
(detail)
2227
(65%)
M
72.9
(-)
79.7
(-)
5241
(53%)
51.2
(-)
Positive
Harold, 2009
Stage 1 (USA)
CL
2
(detail)
1159
(58%)
M
73.5
(-)
80.7
(-)
1783
(56%)
68.1
(-)
Positive
Harold, 2009
Stage 1 (Germany)
CL
2
(detail)
555
(64%)
C
70.5
(-)
72.9
(-)
824
(51%)
56.5
(-)
Positive
Heinzen, 2009
GWAS
CL
0
331
(42%)
U
76 + 8
(-)
-
368
(60%)
-
Positive
Helisalmi, 1999
Finland
CL
1
(detail)
106
(73%)
C
72.5 + 5.6
(59-89)
-
123
(62%)
72.6 + 4
(64-87)
Trend
Hu, 2011
* Recently Added *
USA, Canada (Pfizer, GenADA, ADNI)
CL
1
(detail)
1831
(-)
C
-
-
1764
(-)
-
Positive
Hu, 2011
* Recently Added *
Canada (Genizon-REP)
CL
1
(detail)
751
(-)
M
-
-
751
(-)
-
Positive
Juhasz, 2005
Hungary
CL
1
(detail)
52
(69%)
C
-
73 + 8.9
(-)
53
(57%)
71.5 + 7
(-)
Negative
Kim, 2011
* Recently Added *
USA (ADNI-CSF-GWAS)
CL
1
(detail)
96
(42%)
C
-
75 + 7.8
(-)
102
(48%)
75.9 + 5.1
(-)
Positive
Lambert, 1998 (I)
Overlaps with
Lambert, 2002
2
(detail)
293
(-)
-
-
-
310
(-)
-
n.a.
Lambert, 1998 (II)
Overlaps with
Lambert, 2002
3
(detail)
573
(-)
-
-
-
509
(-)
-
n.a.
Lambert, 2002
France
CL
2
(detail)
675
(63%)
C
69.6 + 8.5
(-)
72.9 + 8.5
(-)
657
(63%)
73.3 + 8.6
(-)
Positive
Lambert, 2004
France (pooled)
CL
2
(detail)
124
(-)
C
-
-
412
(64%)
79 + 8
(-)
Positive
Lambert, 2009
GWAS
CL
0
2025
(66%)
C
68.3 + 9
(-)
73.7 + 8.9
(-)
5328
(61%)
73.8 + 5.4
(-)
Positive
Laws, 1999
Australia
CL
1
(detail)
232
(-)
C
-
-
406
(-)
-
Positive
Laws, 2002
Australia
CL
1
(detail)
20
(45%)
N
-
65.6 + 3.3
(-)
40
(43%)
61.2 + 2.5
(-)
Positive
Lee, 2008
USA (NIA)
CL
0
328
(62%)
M
-
73.3 + 7.1
(-)
236
(58%)
78.1 + 9.1
(-)
Positive
Li, 2008
UK1
CL
1
(detail)
342
(-)
C
-
-
346
(-)
-
Positive
Li, 2008
USA (WashU)
CL
1
(detail)
396
(-)
C
-
-
367
(-)
-
Positive
Li, 2008
UK2
CL
1
(detail)
278
(-)
C
-
-
311
(-)
-
Positive
Li, 2008
USA (UCSD)
CL
1
(detail)
235
(-)
C
-
-
322
(-)
-
Positive
Li, 2008
GWAS
0
-
-
-
-
-
-
Positive
Licastro, 1999
Overlaps with
Casadei, 1999
CL
1
(detail)
260
(61%)
C
-
73.8 + 1
(-)
186
(33%)
60 + 1
(50-92)
n.a.
Lynch, 2008
Ireland
CL
2
(detail)
112
(-)
C
-
-
107
(-)
-
Negative
Naj, 2011
* Recently Added *
USA (ADGC-GWAS)
CL
1
(detail)
8309
(61%)
M
-
-
7366
(58%)
-
Positive
Nicodemus, 2004
USA
CL
5
(detail)
547
(66%)
M
-
74.3 + 8.4
(-)
298
(52%)
68 + 8.9
(-)
Positive
Papassotiropoulos, 2005
I (Greece)
CL
1
(detail)
134
(-)
C
-
-
45
(-)
-
Positive
Papassotiropoulos, 2005
II (Germany, Switzerland)
CL
1
(detail)
150
(-)
C
-
-
216
(-)
-
Positive
Parker, 2005
USA
CL
2
(detail)
180
(71%)
C
70.8 + 8.1
(-)
-
141
(59%)
72.3 + 8.4
(51-89)
Positive
Potkin, 2009
GWAS
CL
0
172
(47%)
C
-
75.3 + 7.3
(-)
209
(48%)
75.9 + 5.1
(-)
Positive
Randall, 2009
Overlaps with
Parker, 2005
CL
2
(detail)
181
(71%)
C
-
-
119
(52%)
-
n.a.
Roks, 1998
Netherlands
PO
1
(detail)
99
(-)
C
57 + 5
(-)
63 + 4.9
(-)
109
(-)
61 + 3.3
(-)
Positive
Roks, 1998
Spain
PO
1
(detail)
78
(-)
C
57 + 5.8
(-)
63 + 8.2
(-)
132
(-)
63 + 8.2
(-)
Positive
Roks, 2002
Netherlands
PO
1
(detail)
360
(76%)
C
-
82.4 + 7.1
(-)
247
(85%)
74.7 + 3.6
(-)
Positive
Seshadri, 2010
GWAS
CL
1
(detail)
9511
(-)
M
-
-
36136
(-)
-
Positive
Shen, 2010
* Recently Added *
USA (ADNI-MRI-GWAS)
CL
1
(detail)
175
(45%)
C
-
75.5 + 7.6
(-)
203
(45%)
76.1 + 5
(-)
Positive
Song, 1998
USA, Canada
CL
1
(detail)
88
(-)
C
76.1 + 7.8
(-)
-
112
(-)
69.9 + 12.5
(-)
Negative
Thome, 1999
Germany
CL
1
(detail)
80
(-)
C
-
-
306
(-)
-
Negative
Trebunova, 2009
Slovakia
CL
1
(detail)
69
(55%)
C
-
73.2 + 9.9
(-)
122
(51%)
73.2 + 10.7
(-)
Positive
Wang, 2000
USA
CO
3
(detail)
237
(50%)
C
72.8 + 5.7
(60-93)
-
274
(59%)
77.4 + 6.6
(60-102)
Positive
Yu, 2007
USA
CL
12
(detail)
193
(53%)
C
-
-
232
(59%)
-
Positive
Zill, 2001
Germany
CL
2
(detail)
89
(56%)
C
-
73 + 9
(-)
118
(53%)
47 + 12
(-)
Negative
Zurutuza, 2000
France
CL
3
(detail)
388
(59%)
C
65.4 + 9.4
(40-90)
-
386
(54%)
66.9 + 10.4
(43-92)
Trend
African Descent
Tycko, 2004
USA
CL
3
(detail)
142
(-)
C
-
-
251
(-)
-
Negative
Asian
Chen, 1999
China
CL
1
(detail)
196
(74%)
M
-
79.5 + 8.5
(-)
180
(66%)
79.2 + 7.5
(-)
Negative
Hu, 2000
Taiwan
CL
1
(detail)
82
(-)
C
-
78.2
(62-96)
110
(-)
79.2
(67-87)
Negative
Takei, 2009
Japan
CL
5
(detail)
547
(72%)
C
73 + 6.9
(60-93)
-
715
(54%)
73 + 6.8
(-)
Positive
Toji, 1999
Japan
1
(detail)
118
(71%)
C
67.6 + 9.5
(-)
-
118
(74%)
65.1 + 8.5
(-)
Negative
Wakutani, 2002
Japan
CL
1
(detail)
241
(-)
U
-
-
352
(-)
-
Negative
Yamagata, 2001
Japan
2
(detail)
27
(52%)
N
-
78.5 + 8.7
(56-90)
20
(55%)
75.3 + 13
(38-99)
Negative
Yang, 2003
China
CL
4
(detail)
183
(58%)
C
-
74.6
(-)
133
(48%)
74.5
(-)
Positive
Hispanic
Tycko, 2004
USA
CL
3
(detail)
230
(-)
C
-
79.5 + 6.6
(65-103)
359
(-)
-
Negative
Other/Mixed
Mui, 1996
USA
CL
1
(detail)
94
(-)
M
-
-
49
(-)
-
Trend
Naj, 2010
USA (discovery)
CL
2
(detail)
931
(65%)
M
74.4 + 8.1
(-)
-
1104
(62%)
73.8 + 7.8
(-)
Positive
Naj, 2010
USA (replication)
CL
2
(detail)
1338
(-)
M
-
-
2003
(-)
-
Positive
Para-Bonilla, 2003
Colombia
3
(detail)
79
(71%)
C
68 + 3.8
(-)
-
67
(-)
71.5 + 12.4
(-)
Positive
Perry, 2001
USA
CL
2
(detail)
111
(78%)
M
70.8 + 7.8
(-)
71.3 + 7.7
(-)
78
(76%)
75.2 + 7.6
(-)
Negative
Rebeck, 1999
USA
CL
2
(detail)
183
(-)
M
-
-
250
(-)
-
Negative
Town, 1998
USA
CL
1
(detail)
190
(48%)
C
73.4 + 6.2
(-)
-
132
(58%)
71.6 + 7.2
(-)
Positive
Contact us
if you are an author of an association study regarding this gene and do not find your study in this table or find errors in the representation of your study details.
2. Family-Based Studies (by ethnic group)
Affecteds
Unaffecteds
Study
Population
# Polys
# Families
# Subjects
(% women)
DX
Onset Age
(range)
Age
(range)
# Subjects
(% women)
Age
(range)
Result
Comment
Caucasian
Bertram, 2008
GWAS
0
-
-
-
-
-
-
Positive
Lee, 2008
Overlaps with
Lee, 2009 (CC)
0
328
776
(-)
M
73.9 + 7.5
(-)
77.2 + 7.5
(-)
873
(-)
-
Positive
Nicodemus, 2004
USA
5
(detail)
248
592
(26%)
M
68
(-)
-
452
(-)
-
Negative
Wijsman, 2011
* Recently Added *
USA (NIA, NCRAD)
0
611
1848
(-)
M
-
-
1991
(-)
-
Positive
Contact us
if you are an author of an association study regarding this gene and do not find your study in this table or find errors in the representation of your study details.
Source:
Source of case population -> “CL” (clinic-based), “PO” (population-based), or “CO” (community-based).
# Polys:
Number of polymorphisms tested per gene and per sample.
Onset Age and Age:
Mean or median age at onset or examination, respectively.
DX:
Criteria used to determine AD diagnosis -> "C" (clinical AD diagnosis), "N" (neuropathological AD diagnosis), "M" (mixed, i.e. AD sample contains both clinical and neuropathological cases), "U" (unknown).
Result:
Overall conclusion reached by authors of the original publication (“positive” usually indicates significant (P<0.05) association in at least one of the performed analyses, and “negative” indicates no evidence for significant association, while “trend” indicates results in between); results obtained in duplicate or largely overlapping samples are listed as "n.a.".
(-)
: Either no data provided or in case of overlap, data included in original study.
AlzGene Recent Updates
APOE
PICALM
MS4A6A
MS4A4A
MS4A4E
EPHA1
CR1
CLU
CD33
CD2AP
BIN1
ABCA7
ARID5B
CELF2
APOC4
BCAM
CLPTM1
PVRL2
LOC3884...
TNK1
MYH13
TOMM40
PCK1
SORL1
LMNA
PGBD1
UBD
GWA_7p1...
GAB2
GOLM1
GWA_15q...
GWA_9p2...
MTHFD1L
LRAT
FAM113B
PCDH11X
GWA_14q...
ATXN1
ADAM10
CD36
DPYS
TGM4
HMMR
LAMB1
PPP3CB
ADORA2B
MTP18
ESR1
CYP19A1
LIPA
CH25H
IL1RN
LPA
MTR
FAS
CHAT
CHRNA2
CHRNA6
CHRNA7
HTR2A
PIN1
NTRK2
SERPINA...
DLST
MAPT/ST...
APOC1
LRRTM3
REN
TNFRSF1...
PIK3R1
FYN
PPP1R3A
NDUFA8
MAPK8IP...
GRIN2B
TNFRSF1...
NDUFA6
PTGS2
HFE
ABCA1
LRP8
PPARG
APBB2
LDLR
IL10
BDNF
PPARA
SOAT1
NOS3
CHRNB2
CETP
MARCH5
ACE
PON1
PON2
CDK5
CTSD
VR22
LRP1
IL6
BACE1
BACE2
PSEN2
PLAU
GSTO1
GSTO2
PRSS11
IDE
CST3
PRNP
NCSTN
TF
MME
PSEN1
TCF7L2
DYRK1A
SORCS2
SORCS3
F11R
TUBB
GRN
NEDD9
ARMS2
SMAD3
VCP
WWC1
DNM2
EBF3
EIF2AK2
SEC24C
SGPL1
ABCG1
LSS
ABCG4
CYP39A1
NCAPD2
GAPDHS
ACTA2
KCNMA1
MYST4
SCD
ANK3
GOT1
SORCS1
TAP2
ENTPD7
DNMBP
CXCL10
VPS26A
C12orf4...
CCNT1
DAPK1
POMT1
IREB2
HMGCR
IGF1R
ABCB1
DSC1
NQO1
HMOX1
LIPC
HMGCS1
RFTN1
APOA1BP
FDPS
HMGCS2
PRKAB2
ADAM12
DHCR24
SOS2
ABCC9
GRB14
HK1
IRS1
NEUROD1
PDE3B
PPARGC1...
PPP1CC
SLC2A2
HECTD2
PITRM1
TARDBP
CDKN2A
IGF1
CSK
CBLC
CARD8
HMOX2
TRPC4AP
GSTZ1
NUMB
POMT2
TMEM63C
THRA
TACR2
OLIG2
TTR
TNMD
EFNA5
MAGI2
CAND1
PPIL2
CDKN2BA...
PTPLA
ACAT2
CHRNB4
DGKB
GWA_10q...
GWA_18q...
GWA_3q2...
HPCAL1
EXOC3L2
GWA_3p2...
ZNF292
PATHWAY...
PATHWAY...
PATHWAY...
TP63
TMEM132...
RGS6
NXPH1
NCAM2
GLOD4
EPHA4
EPC2
CCDC134
ATP6V0A...
ARL5B
AGPAT1
AlzGene Top Results
Top Results Details
1.
APOE_e2/3/4
2.
BIN1
3.
CLU
4.
ABCA7
5.
CR1
6.
PICALM
7.
MS4A6A
8.
CD33
9.
MS4A4E
10.
CD2AP
AlzGene Stats
Studies: 1395
Genes: 695
Polymorphisms: 2973
Meta-analyses: 320
Proud supporter of the AlzGene database.
The PDGene database
is supported by a grant from
The Michael J. Fox Foundation
in partnership with the
Alzheimer Research Forum
.
NCRAD
The National Cell Repository for Alzheimer Disease seeks to recruit 1,000 families with two or more living brothers or sisters who have been diagnosed with late onset Alzheimer’s disease.
ALSGene
AlzGene
MSGene
PDGene
SZGene
An up-to-date collection of all published genetic association studies.